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Abstract
Background: Few studies have compared the impact of different antiretroviral regimens on residual immune
activation and inflammation with discordant results. Aim of the study was to investigate the impact of various
antiretroviral regimens on markers of immune activation and inflammation during the first two years of effective
therapy.
Methods: We studied HIV-infected antiretroviral-naïve patients who began cART with either abacavir/lamivudine or
tenofovir/emtricitabine, combined with ritonavir-boosted lopinavir (LPV/r), atazanavir (ATV/r) or efavirenz (EFV). All the
patients had a virological response within 6 months, which was maintained for 2 years with no change in their ART
regimen. C-reactive protein (hs-CRP), interleukin-6 (IL-6), soluble CD14 (sCD14), monokine induced by interferon-γ (MIG)
and interferon-γ-inducible protein-10 (IP-10) were measured in stored plasma obtained at cART initiation and 24 months
later. Mean changes from baseline were analyzed on loge-transformed values and multivariable linear regression
models were used to study the effect of the treatment components, after adjusting for factors that might have
influenced the choice of ART regimen or biomarker levels. Differences were expressed as the mean fold change
percentage difference (Δ).
Results: Seventy-eight patients (91% males) with a median age of 43 years met the inclusion criteria. Their median
baseline CD4 cell count was 315/mm3 and HIV-1 RNA level 4.6 log10 copies/ml. During the 2-years study period, IL-6,
IP-10 and MIG levels fell significantly, while hs-CRP and sCD14 levels remained stable. IP-10 and MIG levels declined
significantly less strongly with ATV/r than with EFV (IP-10Δ -57%, p = 0.011; MIGΔ -136%, p = 0.007), while no difference
was noted between LPV/r and EFV. The decline in IL-6 did not differ significantly across the different treatment
components.
Conclusions: After the first 2 years of successful cART, IL-6, IP-10 and MIG fell markedly while hs-CRP and sCD14 levels
remained stable. The only impact of ART regimen was a smaller fall in markers of immune activation with ATV/r than
with EFV. Our results suggest that these markers could be worthwhile when evaluating new antiretroviral drugs.
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Background
Antiretroviral therapy (ART) leads to a dramatic reduction
in HIV-related morbidity and mortality [1] and currently
suppresses viral replication in the vast majority of compli-
ant patients [2]. Most treatment guidelines recommend
early initiation of ART, based mainly on nucleoside re-
verse transcriptase inhibitors (NRTI) combined with non-
nucleoside reverse transcriptase inhibitors (NNRTI) or
protease inhibitors (PI) [3,4]. However, despite viral
suppression and quantitative immune restoration in
most patients, signs of immune activation and inflam-
mation persist [5,6]. This may be due in part to ongoing
low-level viral replication [7], the coinfection with other
chronic viruses such as cytomegalovirus and Epstein-
Barr virus [8,9] and to the consequences of mucosal
immune dysfunction that is characterized by a pro-
found depletion of CD4 + T-cells during the early acute
infection, and a progressive loss of the ability to main-
tain the intestinal barrier function, allowing transloca-
tion of the intestinal microbial flora into the systemic
circulation which induces immune activation and in-
flammation cascades [10]. An additional factor that
may contribute to this persistence is the perturbation
of immune regulatory mechanisms, such as regulatory
T-cells or the immune regulatory cytokines such as
interleukin-10 [11].
By comparison with HIV-uninfected individuals, sev-
eral studies have shown an excess of comorbidities in
HIV-infected patients on virologically effective treat-
ment, including metabolic disorders [12], decreased
bone mineral density with an increased risk of fractures
[13], an elevated cardiovascular risk [14], and cancers
[15]. These comorbidities have been attributed to a
higher prevalence of standard risk factors such as
smoking in HIV-infected patients, as well as to past or
present HIV-induced immune depression reflected by
the CD4 cell nadir or the CD4/CD8 cell ratio [16,17], and
to the effect of some antiretroviral drugs [12,18,19]. In
addition, elevated levels of markers of inflammation,
such as interleukin-6 (IL-6) and C-reactive protein
(CRP), have been linked to increased morbidity and
mortality in both the general and HIV-infected popula-
tions [20-22]. The SMART study was the first to dem-
onstrate that mortality in this setting is linked to HIV
replication, inflammatory markers such as IL-6 and sol-
uble CD14 (sCD14), and coagulation markers such as
D-dimers [23]. Since then, several studies have shown
an association between plasma markers of inflamma-
tion and the risk of non AIDS-defining events [24,25].
In the ALLRT cohort, elevated levels of IL-6, sCD14, D-
dimers and soluble tumor necrosis factor receptors
(sTNFR1 and sTNFR2), both prior to and during ART,
were associated with the occurrence of non AIDS-
related morbidities and death [26].
Now that ART is recommended for all HIV-infected
patients, and life expectancy is greatly prolonged by sup-
pressive ART despite the lack of viral eradication, it is
important to compare the potential impact of different
antiretroviral strategies on residual immune activation
and inflammation. There are some arguments to suggest
that different drugs from different classes may have dif-
ferent impact on immune activation and inflammation. In
the Spiral study, a switch from PI-based therapy to a
raltegravir-containing regimen in patients with suppressed
viremia led to a decrease in biomarkers associated with in-
flammation, insulin resistance and hypercoagulability [27].
Few studies have examined the impact of first-line
ART on biomarkers of inflammation and immune acti-
vation, and they have given discordant results [28-31].
These discordant results might reflect differences in
baseline HIV disease status, and/or differences in the
virological response, and/or treatment switches.
We therefore explored the impact of different first-line
ARV regimens on soluble markers of inflammation and
immune activation during the first two years of effective
therapy, while controlling for potential confounders such
as HIV replication, and changes in the initial regimen.
Methods
Study design
We compared the impact of commonly used first-line
antiretroviral drugs on soluble markers of inflammation
and immune activation, while controlling for potential
confounders. In order to avoid the influence of previous
ARV exposure, active viral replication and treatment
switches, we restricted our analysis to a homogenous
group of treatment-naive HIV-infected patients who had
experienced a rapid and persistent virological response
and remained on their initial regimen for 2 years. Be-
cause the biomarkers of interest were not part of the pa-
tients' routine biological monitoring, we restricted our
analysis to patients for whom plasma samples stored at
ART initiation and 2 years later were available. The ana-
lyses were also adjusted for baseline characteristics that
might have influenced the choice of cART regimen or
affected biomarker levels, such as the age, smoking sta-
tus, CD4 cell count, prior AIDS-defining events, plasma
HIV-1 viral load, and hepatitis virus coinfection.
Study population
All HIV-infected patients receiving care in the Infectious
Diseases department of Pitié-Salpêtrière Hospital (Paris,
France) have their clinical, biological and therapeutic find-
ings recorded prospectively in standardized electronic
medical records (NADIS). Biological data obtained in the
hospital, such as HIV RNA levels and immunological pa-
rameters, are directly imported from the laboratory com-
puter system, thus minimizing collection bias. The quality
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of the database is ensured by automated checks during
data capture, and by regular controls and annual assess-
ments. Routine blood tests are performed at each hospital
visit, and residual plasma is stored frozen, being identified
by a serial number.
All HIV-1-infected patients who started first-line
cART between January 2006 and December 2009 were
screened for eligibility, using the hospital database. Pa-
tients were included in this study if they received either
tenofovir-emtricitabine (TDF/FTC) or abacavir-lamivudine
(ABC/3TC), combined with efavirenz or with a ritonavir-
boosted protease inhibitor (atazanavir (ATV/r) or lopinavir
(LPV/r)). In order to control for potential causes of inflam-
mation/activation due to persistent plasma viral replication,
we only studied patients who had a rapid and persistent
virological response, defined by a plasma HIV-1 viral
load (VL) below 400 copies/mL at 6 months and below
50 copies/mL at 24 months, with no values above 1000
copies/ml between month 6 and month 24. Other eligi-
bility criteria included no change in antiretroviral ther-
apy throughout the 24 months of the study, and the
availability of frozen plasma samples obtained at base-
line (D0) and month 24 (M24). The study was approved
by the Pitié-Salpêtrière institutional review board, and
the patients were asked to give their written consent to
the use of their medical information and plasma sam-
ples, as required by French law.
Sample collection and plasma soluble markers
measurements
We selected markers of inflammation and immune activa-
tion that can be reliably measured in frozen plasma. We
evaluated IL-6 and hs-CRP as markers of inflammation,
soluble CD14 (sCD14) as a marker of monocyte activa-
tion, and interferon-γ-inducible protein 10 (IP-10) and
monokine induced by interferon-γ (MIG) as markers of
T-lymphocyte and macrophage activation.
Enzyme-linked immunosorbent assays (ELISA) were
used according to manufacturer’s instructions to quan-
tify IL-6, sCD14 (R&D Quantikine®, HS600B and DC140
respectively) and hs-CRP (Calbiotech®, CR120C). IP-10
and MIG levels were determined on thawed diluted
plasma with Cytometric Bead Array kits (BD™ CBA) on
a BD FACS Canto I according to manufacturer’s instruc-
tions. Coefficients of variation were 6.9-7.8% for IL-6,
7.9–8.5% for hs-CRP, 4.8–7.4% for sCD14, 4% for IP-10
and 9–13% for MIG. Plasma samples were allowed to
thaw for 50 minutes at room temperature before centri-
fugation for 5 minutes at 1000 rpm, followed by distri-
bution into Eppendorf tubes in the amounts required for
each assay kit. Plasma was diluted as recommended by
the kit manufacturers. Standards provided with the kits
were measured in duplicate and the mean value was
used as reference. Samples with values higher than the
highest standard value were further diluted and retested.
D0 and M24 samples from each patient were tested in
the same run.
Statistical analysis
Two NRTI backbone combinations (TDF/FTC vs ABC/
3TC) and three third agents (LPV/r, ATV/r vs EFV)
were compared in a factorial design. Baseline character-
istics were compared between treatment groups by using
the Wilcoxon and chi-squared tests in order to identify
variables associated with the choice of treatment. Be-
cause the marker values were not normally distributed,
they were loge-transformed for analysis. For each marker,
changes between D0 and M24 (mean fold change) were
expressed as the geometric mean of their ratio after loge
transformation. A paired one-sample t test was used to
identify significant differences in the overall changes in
each marker.
Linear regression models were used to investigate the
impact of the different NRTI backbones and the differ-
ent third agents on the biomarker changes. The results
are expressed as the estimated percentage difference be-
tween the mean fold changes observed with a given
drug, using TDF/FTC and EFV as the reference groups
for the comparison. Relationships between baseline cov-
ariables and changes in each biomarker were examined
in univariable linear regression models. These covari-
ables were sex, age, body mass index, smoking status,
hepatitis B or C virus (HBV or HCV) coinfection, prior
AIDS-defining events, and the pre-ART CD4 cell count
and viral load. Baseline covariables associated with
changes in at least one biomarker (p < 0.10) and viral blips
above 50 copies/ml between M6 and M24 were retained
in all multivariable linear regression models in order to
control for factors that might have influenced the choice
of cART regimen or affected biomarker levels. Age and
smoking status were included in the multivariable model
since these variables are known to influence marker levels
[32,33]. Interaction terms between the NRTI backbone
and the third agent were tested for each marker. Sensitiv-
ity analyses were conducted, excluding patients with hepa-
titis virus coinfection. Statistical analyses were run on




Between January 2006 and December 2009, a total of 539
patients began first antiretroviral therapy and remained
under care over two years in our department. Of those,
370 patients had a rapid and persistent virological re-
sponse over the two years. Of them, 280 patients who
began therapy with abacavir/lamivudine or tenofovir/
emtricitabine plus efavirenz, atazanavir/r, lopinavir/r or
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fosamprenavir/r were eligible for the study. The remaining
90 patients were not considered since they either received
no longer recommended antiretroviral therapy such as
combivir and invirase (n = 64) or were included in proto-
cols evaluating new drugs such as darunavir and rilpivir-
ine. Frozen plasma samples at baseline and after two years
were available for 149 patients. Characteristics of patients
who had stored plasma were not different from those did
not have it for age, CD4 cell count, HIV-RNA level, AIDS
defining events and for prescribed antiretroviral therapy.
Two patients who withheld their consent were excluded.
Among the remaining 147 patients, 78 remained on the
same antiretroviral regimen throughout the 2-year study
period and comprised the study population. Modifications
in first ART regimen were due to side effects, drug tox-
icity, or switch to newly available drugs.
The NRTI backbone consisted of TDF/FTC in 61 pa-
tients (78%) and ABC/3TC in 17 patients. The third
agent was EFV in 36 patients (46%), ATV/r in 27 pa-
tients (35%) and LPV/r in 15 patients. At baseline, the
median viral load was 4.6 log10 copies/mL, the median
CD4 cell count was 315/mm3 and the median CD4/CD8
cell ratio was 0.30. Seven patients (9%) had an AIDS-
defining event. Four patients were HCV-PCR-positive
and two were HBsAg-positive.
Baseline characteristics were well balanced across the
treatment groups, with the following exceptions. As shown
in Table 1, patients prescribed LPV/r had the lowest me-
dian CD4 cell count (177 cells/mm3), a value significantly
different from the median count in patients prescribed
ATV/r (330 cells/mm3) or EFV (342 cells/mm3) (p = 0.020).
Patients prescribed TDF/FTC had a lower median CD4
cell count than patients prescribed ABC/3TC (304 ver-
sus 431 cells/mm3; p = 0.008). Four patients prescribed
LPV/r had an AIDS-defining event, compared to only
one patient prescribed ATV/r and two patients
prescribed EFV (p = 0.030). All the patients with hepa-
titis virus coinfection were prescribed LPV/r (p <
0.001).
Changes in immunovirological status during the first two
years of effective cART
As requested, all the patients had plasma HIV viral loads
below 400 copies/ml at M6 and below 50 copies/ml at
M24. At M6, 72 patients (92%) had viral loads below 50
copies/ml. Between M6 and M24, twelve patients (15%)
had isolated viral loads above 50 copies/ml (median 63 cop-
ies/ml; range 54 to 210). Among patients receiving TDF/
FTC, 10 patients (16%) had isolated plasma viral loads
above 50 copies/ml, compared to 2 patients (12%) receiving
ABC/3TC (p = 0.64). Among patients receiving EFV, 3 pa-
tients (9%) had isolated viral loads above 50 copies/ml,
compared to 4 patients (17%) receiving ATV/r and 5 pa-
tients (33%) receiving LPV/r (p = 0.08). During the 2-year
study period, the CD4 cell count increased by 216/mm3
and the CD4/CD8 ratio by 0.42. At M24, the median CD4
cell count was 530/mm3 (IQR 393 to 683) and the median
CD4/CD8 ratio was 0.76 (IQR 0.47 to 1.1). No patient
developed AIDS defining event during the two years of
treatment, while 11 patients experienced a non-AIDS de-
fining event, consisting of pneumonia (n = 5), nephropathy
(n = 4), osteoporosis (n = 1) and idiopathic gout (n = 1).
None of the 28 smoking individuals quitted smoking while
on treatment.
Changes in markers of inflammation and immune
activation during the first two years of effective cART
At baseline, the only difference in plasma biomarkers
levels across the treatment groups was a higher IL-6
level in patients prescribed LPV/r (median 2.17 pg/ml)
than in patients prescribed ATV/r or EFV (median 1.2
and 1.6 pg/mL, respectively; p = 0.040).
Table 1 Baseline characteristics of the patients
N (%) or median (interquartile range)
Total n = 78 TDF/FTC n = 61 ABC/3TC n = 17 EFV n = 36 ATV/r n = 27 LPV/r n = 15
Sex: Male 71 (91%) 56 (91%) 15 (88%) 34 (94%) 22 (81%) 15 (100%)
Age, years 43 (34-47) 44 (35-49) 38 (32-43) 42 (34-46) 44 (35-48) 42 (33-55)
Body mass index 23 (22-24) 23 (22-25) 22 (21-24) 23 (22-25) 22 (21-25) 22 (21-24)
Current smokers 28 (36%) 25 (41%) 3 (18%) 14 (39%) 6 (22%) 8 (53%)
Viral hepatitis coinfection 6 (8%) 5 (8%) 1 (6%) 0 0 6 (40%)
Prior AIDS 7 (9%) 5 (8%) 2 (12%) 2 (6%) 1 (4%) 4 (27%)
CD4/mm3 315 (217-409) 304 (190-384) 431 (330-512) 342 (262-402) 330 (263-446) 177 (72-299)
CD8/mm3 959 (660-1345) 949 (656-1335) 1053 (762-1468) 981 (774-1240) 1111 (646-1506) 709 (454-1109)
CD4/CD8 ratio 0.30 (0.19-0.46) 0.28 (0.17-0.41) 0.49 (0.22-0.59) 0.33 (0.19-0.46) 0.29 (0.24-0.49) 0.16 (0.13-0.38)
Viral load (log10 copies/mL) 4.6 (4.1-5.2) 4.7 (4.3-5.2) 4.4 (3.6-4.9) 4.8 (4.3-5.2) 4.4 (4-4.9) 5.1 (4.6-5.3)
Viral load > 5 log10 36%
TDF, tenofovir; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; EFV, efavirenz; ATV/r, atazanavir/ritonavir; LPV/r, lopinavir/ritonavir.
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At M24, IL-6, IP-10 and MIG levels were significantly
lower than at baseline (-40%, -59% and -74%, respect-
ively), while sCD14 levels were unchanged (Table 2).
The hs-CRP level fell by 23% but the change was not
statistically significant.
Impact of individual antiretroviral drugs on markers of
inflammation and immune activation
Based on univariable linear regression models, between-
group comparisons and the literature, the following vari-
ables were selected for multivariable analyses: age, smoking
status, prior AIDS-defining events, baseline CD4 cell count,
baseline viral load, hepatitis B or C virus coinfection, and
viral blips above 50 copies/ml between M6 and M24. After
adjustment for these variables and for the ARTcomponents
(the NRTI backbone and the third agent), no significant dif-
ference in the decline in the IL-6 level was found between
the TDF/FTC and ABC/3TC groups (mean fold change
percentage difference Δ 4%; p = 0.90) (Table 3). Compared
to EFV, no significant difference in the change of IL-6 was
associated with ATV/r or LPV/r use. In contrast, the choice
of treatment regimen influenced the decline in IP-10 and
MIG levels: the decline in both IP-10 (Δ = -57%, p = 0.011)
and MIG (Δ = -136%; p = 0.007) was significantly smaller
with ATV/r than with EFV, while no significant difference
was found between LPV/r and EFV (IP-10 Δ = -4%; p =
0.87; MIG Δ = -48%; p = 0.44) or between ABC/3TC and
TDF/FTC (IP-10 Δ = 30%; p = 0.09; MIG Δ = 24%; p = 0.47).
No interaction was found between the NRTI backbone
and the third agent for any of the marker, p-values of
the interaction terms were 0.19, 0.26, 0.72, 0.34 and 0.91
for IL-6, hs-CRP, sCD14, IP-10 and MIG respectively.
Similar results were obtained in sensitivity analyses that
excluded patients with hepatitis virus coinfection.
Discussion and conclusions
This observational study of changes in markers of in-
flammation and immune activation during the first two
years of unchanged virologically effective first-line cART
regimens (tenofovir- or abacavir-based NRTI backbone
plus efavirenz, atazanavir/r or lopinavir/r) shows that the
choice of the third antiretroviral agent influenced the de-
gree of decline in markers of T-lymphocyte and macro-
phage activation. Plasma levels of IL-6, IP-10 and MIG
fell by at least 40% in all the treatment groups, while the
decline in hs-CRP levels failed to reach statistical signifi-
cance and sCD14 levels were unchanged. The only ob-
served difference between the treatment groups was that
the T-lymphocyte and macrophage activation markers
IP-10 and MIG fell less markedly in patients receiving
ATV/r than in patients receiving EFV; no difference was
found between LPV/r and EFV. Our patient population
represents the naïve patients who initiated cART be-
tween January 2006 and December 2009 with a moder-
ate immune deficit and a median viral load slightly
below 100000 copies/ml and who experienced a rapid
virological response in usual care in France.
Several aspects of study design are important in study-
ing the influence of different antiretroviral drugs on bio-
marker variations in patients starting first-line therapy.
First, it is important to control for viral replication, which
is a major cause of persistent immunological activation
Table 2 Changes from M0 to M24 in plasma markers of inflammation and immune activation (loge-transformed values)
Total n = 78 TDF/ FTC n = 61 ABC/ 3TC n = 17 EFV n = 36 ATV/r n = 27 LPV/r n = 15
IL-6 Baseline (pg/ml) 1.6 (1.1-2.5) 1.6 (1.1-2.6) 1.2 (0.99-1.7) 1.6 (1.1-2.5) 1.2 (0.88-2.4) 2.17 (1.1-7.4)
Mean fold change (95% CI) 0.60 (0.49, 0.74) 0.60 (0.48, 0.77) 0.60 (0.36, 0.99) 0.59 (0.42, 0.83) 0.82 (0.64, 1.05) 0.36 (0.20, 0.67)
P value* <0.001
hs-CRP Baseline (mg/L) 4 (2.2-15) 4.2 (2.3-15) 2.7 (1.8-9.4) 3.9 (2.2-17.8) 3 (2-5.9) 7.5 (2.9-20)
Mean fold change (95% CI) 0.77 (0.57, 1.1) 0.81 (0.56, 1.20) 0.66 (0.33, 1.30) 0.76 (0.46, 1.26) 0.88 (0.54, 1.44) 0.63 (0.27, 1.47)
P value 0.11
sCD14 Baseline (106 pg/ml) 2.6 (2.1-3.1) 2.6 (2.2-3.1) 2.5 (2-3.1) 2.5 (2.2-3) 2.6 (1.7-3.1) 3.1 (2-3.4)
Mean fold change (95% CI) 1.00 (0.93, 1.1) 1.00 (0.93, 1.10) 0.96 (0.79, 1.15) 0.95 (0.85, 1.06) 1.10 (0.93, 1.26) 1.00 (0.85, 1.20)
P value 0.82
IP-10 Baseline (pg/ml) 664 (431-960) 630 (435-974) 721 (431-895) 692 (447-996) 549 (389-781) 798 (470-1326)
Mean fold change (95% CI) 0.41 (0.35, 0.49) 0.44 (0.36, 0.52) 0.37 (0.27, 0.49) 0.34 (0.28, 0.42) 0.53 (0.40, 0.71) 0.43 (0.27, 0.67)
P value <0.001
MIG Baseline (pg/ml) 1532 (980-2804) 1534 (1004-2804) 1431 (938-2562) 1908 (1093-3799) 1182 (920-2201) 1611 (887-2444)
Mean fold change (95% CI) 0.26 (0.19, 0.33) 0.25 (0.18, 0.35) 0.27 (0.17, 0.42) 0.16 (0.10, 0.24) 0.39 (0.30, 0.51) 0.39 (0.22, 0.70)
P value <0.001
TDF, Tenofovir; FTC, Emtricitabine; ABC, Abacavir; 3TC, Lamivudine; EFV, Efavirenz; ATV/r, Atazanavir/ritonavir; LPV/r, Lopinavir/ritonavir; IL-6, Interleukin-6; hs-CRP,
Highly sensitive C-reactive protein; sCD14, soluble CD14; 1P10, Interferon-γ-Inducible Protein 10; MIG, Monokine induced by interferon-γ; CI, Confidence Interval.
*One-sample Student’s t test of the change of each marker in the overall study sample.
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and inflammation. As a result, the approach used in ran-
domized trials, which includes all patients independently
of their virological response, may not be appropriate. Fur-
thermore, removal of patients with uncontrolled viral load
from a randomized trial will result in a simple observa-
tional study. Despite the lack of randomization in our
study, baseline characteristics were well balanced across
the treatment groups, and factors that might have influ-
enced the choice of cART regimen or the time course of
the markers of interest were systematically included in the
analyses. In addition, all the patients under care in the In-
fectious Diseases department of Pitié-Salpêtrière Hospital
were screened for eligibility criteria, thus avoiding any
major selection bias. However, one cannot exclude that
unrecognized confounding regarding treatment selection
could be present. In our study, the strict inclusion criteria
regarding the viral replication resulted in a limited sample
size. However, even with this sample size, significant dif-
ferences were detected for some of the comparisons. In
addition, most p-values of non-significant tests were above
0.15 indicating that for most comparisons, power was not
an issue. It is possible that the freezing of plasma sample
could have modified the marker levels and diminished our
ability to detect differences. However, all the groups of
antiretroviral regimens were studied similarly and this
should not have biased the comparison between groups.
Moreover, as in most published studies, studying thawed
plasma allowed to study all marker dosages simultan-
eously in the same experiment, limiting the inter-
individual variability. The high variability of inflammatory
markers between individuals could have precluded seeing
differences between treatment groups.
Elevated IL-6 and CRP levels before antiretroviral
treatment initiation or after treatment interruption have
Table 3 Regression analyses comparing the impact of antiretroviral therapy components on biomarker changes
Univariable Multivariable*
Marker Antiretrovirals Mean fold change percentage difference
(95% CI)




ABC/3TC 1 (-67 to 41) 0.97 4 (-80 to 49) 0.90
EFV Ref.
ATV/r -39 (-120 to 12) 0.16 -20 (-101 to 28) 0.48
LPV/r 38 (-8 to 63) 0.09 43 (-23 to 74) 0.15
hs-CRP TDF/FTC Ref.
ABC/3TC 18 (-77 to 62) 0.60 7 (-155 to 66) 0.88
EFV Ref.
ATV/r -16 (-139 to 43) 0.68 -34 (-203 to 41) 0.47
LPV/r 16 (-97 to 63) 0.67 41 (-29 to 82) 0.39
sCD14 TDF/FTC Ref.
ABC/3TC 7 (-13 to 3) 0.48 14 (-8 to 31) 0.18
EFV Ref.
ATV/r -14 (-36 to 4) 0.13 -19 (-43 to 1) 0.06
LPV/r -6 (-31 to 14) 0.57 -4 (-36 to 21) 0.77
IP10 TDF/FTC Ref.
ABC/3TC 16 (-22 to 42) 0.36 30 (-6 to 54) 0.09
EFV Ref.
ATV/r -55 (-118 to -12) 0.01 -57 (-120 to -11) 0.011
LPV/r -26 (-92 to 17) 0.27 -4 (-80 to 39) 0.87
MIG TDF/FTC Ref.
ABC/3TC -8 (-103 to 42) 0.80 24 (-62 to 65) 0.47
EFV Ref.
ATV/r -146 (-306 to -45) 0.001 -136 (-339 to -27) 0.007
LPV/r -151 (-395 to -31) 0.006 -48 (-297 to 45) 0.44
TDF, Tenofovir; FTC, Emtricitabine; ABC, Abacavir; 3TC, lamivudine; EFV, Efavirenz; ATV/r, Atazanavir/ritonavir; LPV/r, Lopinavir/ritonavir; IL6, Interleukin-6; hs-CRP,
Highly-sensitive C-reactive protein; sCD14, soluble CD14; 1P10, Interferon-γ-inducible protein 10; MIG, Monokine induced by interferon-γ; CI, Confidence Interval.
*Adjusted for age, smoking, prior AIDS, baseline CD4 cell count, baseline HIV viral load, HCV or HBV coinfection, and viral blips.
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been linked to a higher risk of AIDS-defining events and
death [23,34]. In our study, IL-6 levels fell during the
first two years of effective antiretroviral therapy, and the
decline did not differ significantly between the NRTI
backbones or across the different third agents. These re-
sults are consistent with those of the HEAT and ACTG
A5224 trials [28,29]. With regard to hs-CRP, we found
that its levels fell slightly although not significantly, with
marked inter-individual differences and no differential
effect of the studied antiretroviral drugs. In the ACTG
A5224, HEAT and NICE trials, CRP levels either rose or
fell after cART initiation, while a differential effect of
antiretroviral drugs was found in ACTG A5224 trial but
not in the HEAT or the NICE trials [28-30]. The high
inter-individual variability, differences in study designs,
such as discussed above, and in baseline characteristics
may explain the discordant results.
Elevated plasma sCD14 levels are an independent pre-
dictor of death among HIV-infected patients [35]. SCD14,
a marker of monocyte activation that correlates with HIV
viremia, and is also considered to be a marker of microbial
translocation across the intestinal mucosa, correlating
positively with plasma lipopolysaccharide levels as being
its soluble receptor [36,37]. Despite 2 years of effective
antiretroviral therapy, sCD14 levels did not change signifi-
cantly, in keeping with previous reports, suggesting that
regimens used in our study may not restore the intestinal
barrier function, resulting in persistent microbial trans-
location and immune activation [36,38]. Previous study
has reported that among treated HIV-infected patients,
persistent HIV-DNA in the gut correlates with levels of
microbial translocation and immune activation [39]. Inter-
estingly, Taiwo B et al. have recently reported that an
NRTI-sparing regimen consisting of boosted darunavir
plus raltegravir led to a decline in sCD14, IL-6 and IP-10
levels [40], suggesting that integrase inhibitors may be
more effective in this respect than other antiretroviral
drugs.
Persistent immune activation despite virologically
effective therapy has been linked to immunological
failure [41,42]. While IL-6, hs-CRP, sCD14 and IP-10
have been studied in other studies, MIG has not been
evaluated in the context of naïve patients initiating
cART. IP-10 (CXCL-10) and MIG (CXCL-9), two che-
mokines induced by interferon gamma, specifically tar-
get lymphocytes, particularly activated T cells, as well as
macrophages, and are critical mediators of T cell migra-
tion during T-cell-dependent immune responses [43].
High levels of these chemokines reflect immunological ac-
tivation in HIV-infected patients [44]. A recent study has
shown that elevated plasma IP-10 levels in primary HIV-1
infection are strongly predictive of rapid HIV disease pro-
gression [45]. In our study, IP-10 and MIG levels showed
the largest decline among the studied biomarkers during
the first two years of effective cART, running parallel to
the fall in plasma viremia. IP-10 and MIG were also the
only markers for which a differential effect of the studied
antiretroviral drugs was observed. The fall in both markers
was larger with EFV than with ATV/r. To investigate
whether these differences could be explained by the
change in CD4 cell count, analyses were made adjusting
for the change of CD4 cell count and differences were still
significant and could not be explained by the change in
CD4 cell count. We hypothesize that other ART-mediated
mechanisms such as the more rapid decay in HIV-RNA in
the first 14 days of treatment initiation associated with
EFV than with ATV/r observed in a randomized study
[46] could explain, at least partly, the observed difference
between EFV and ATV/r. However, it is unclear whether
this has any clinical implications. To our knowledge, the
differential impact of antiretroviral drugs on IP-10 and
MIG has not previously been studied in naïve HIV-
infected patients.
The differential effect of the studied antiretroviral drugs
on changes of two immune activation markers such as IP-
10 and MIG levels suggests that these markers could be
worthwhile when evaluating new antiretroviral drugs. The
presence of sCD14 despite two years of viral suppression
reflects the persistence of immune activation, and may
contribute to the maintenance of residual viremia and
HIV DNA reservoirs [47]. With the growing interest for
finding a cure for HIV infection and with the preoccupa-
tion of long-term management of HIV-infected individ-
uals, it is key to assess the capacity of new drugs and new
combinations of drugs to drive immune activation and in-
flammation down.
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